You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Updates on Multiple Myeloma and MPNs: Findings From the 2017 Hematology Conference

  • Authors: Richard Stone, MD; Maria-Victoria Mateos, MD, PhD; Noopur Raje, MD; Sagar Lonial, MD; Ruben Mesa, MD; Vincent Rajkumar, MD
  • CME / ABIM MOC / CE Released: 12/28/2017
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 12/28/2018
Start Activity


Target Audience and Goal Statement

This activity is intended for hematologists, oncologists, pathologists, emergency medicine physicians, pharmacists, and nurses.

The goal of this activity is to provide education on recently reported study findings on multiple myeloma (MM) and myeloproliferative neoplasms.

Upon completion of this activity, participants will have increased knowledge regarding the:

  • Most significant findings from clinical trials evaluating treatment strategies for MM or myeloid malignancies presented at the 2017 annual hematology meeting
  • Strategies for integrating new data about the management of MM or myeloid malignancies presented at the 2017 annual hematology meeting into clinical practice to improve care for patients


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Richard Stone, MD

    Professor of Medicine, Harvard Medical School; Director, Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Disclosures

    Disclosure: Richard M. Stone, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie, Inc.; Agios Pharmaceuticals; Amgen Inc.; Celator/Jazz Pharmaceuticals; Celgene Corporation; FujiFilm; Janssen Pharmaceuticals, Inc; Juno Therapeutics, Inc.; Karyopharm Therapeutics; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Seattle Genetics
    Other: Data Safety Monitoring Board for Celgene Corporation

    Dr Stone does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Stone does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Faculty

  • Maria-Victoria Mateos, MD, PhD

    Professor, University Hospital of Salamanca, Salamanca, Spain

    Disclosures

    Disclosure: Maria-Victoria Mateos, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.
    Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.

    Dr Mateos does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Mateos does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Noopur Raje, MD

    Professor of Medicine, Harvard Medical School; Clinical Director, Center for Myeloma, Massachusetts General Hospital, Boston, Massachusetts, United States

    Disclosures

    Disclosure: Noopur Raje, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Roche; Takeda Pharmaceuticals North America, Inc.
    Received grants for clinical research from: AstraZeneca Pharmaceuticals LP

    Dr Raje does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Raje does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Sagar Lonial, MD

    Professor and Chair of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States

    Disclosures

    The opinions expressed are those of Dr. Lonial and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr. Lonial’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

    Disclosure: Sagar Lonial, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Takeda Pharmaceuticals North America, Inc.

    Dr Lonial does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Lonial does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Ruben Mesa, MD

    Director, UT Health San Antonio Cancer Center, San Antonio, Texas, United States

    Disclosures

    Disclosure: Ruben Mesa, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AOP Orphan Pharmaceuticals AG; Novartis Pharmaceuticals Corporation; Shire
    Received grants for clinical research from: CTI BioPharma Corp.; Gilead Sciences, Inc.; Incyte Corporation; Promedior, Inc.

    Dr Mesa does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Mesa does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Vincent Rajkumar, MD

    Edward W. and Betty Knight Scripps Professor of Medicine, Mayo Clinic, Rochester, Minnesota, United States

    Disclosures

    Disclosure: Vincent Rajkumar, MD, has disclosed no relevant financial relationships.

    Dr Rajkumar does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Rajkumar does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Vandana Iyer, PhD

    Associate Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Vandana Iyer, PhD, has disclosed no relevant financial relationships.

  • Davecia R. Cameron, MS

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Davecia R. Cameron, MS, has disclosed no relevant financial relationships.

  • Charlotte Warren

    Senior Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

  • Sarah Williams, PhD

    Lead Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Sarah Williams, PhD, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.75 contact hour(s) of continuing nursing education for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

     

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.75 contact hour(s) (0.0.75 CEUs) (Universal Activity Number: 0461-0000-17-206-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Updates on Multiple Myeloma and MPNs: Findings From the 2017 Hematology Conference

Authors: Richard Stone, MD; Maria-Victoria Mateos, MD, PhD; Noopur Raje, MD; Sagar Lonial, MD; Ruben Mesa, MD; Vincent Rajkumar, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 12/28/2017

Valid for credit through: 12/28/2018

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print